» Articles » PMID: 35974164

Critical Appraisal of Serum Urate Targets in the Management of Gout

Overview
Specialty Rheumatology
Date 2022 Aug 16
PMID 35974164
Authors
Affiliations
Soon will be listed here.
Abstract

Gout management involves two broad aspects: treatment of gout flares to provide rapid symptomatic relief and long-term urate-lowering therapy to lower serum urate sufficiently to prevent gout flares from occurring. All of the major rheumatology societies recommend a target serum urate of <5 mg/dl (<0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l), both of which are below the point of saturation for urate and therefore lead to monosodium urate crystal dissolution. In this Review, we describe the rationale for treat-to-target urate approach in the long-term management of gout and the current evidence and controversy around the appropriate serum urate targets.

Citing Articles

Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease.

Massimo G, Dyson N, Olotu F, Khambata R, Ahluwalia A Antioxidants (Basel). 2025; 13(12.

PMID: 39765766 PMC: 11672463. DOI: 10.3390/antiox13121439.


Spatiotemporal Observation of Monosodium Urate Crystals Deposition in Synovial Organoids Using Label-Free Stimulated Raman Scattering.

Chen Y, Chen Z, Wang W, Hua Y, Ji M Research (Wash D C). 2024; 7:0373.

PMID: 38803506 PMC: 11128648. DOI: 10.34133/research.0373.


Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout.

Sun W, Zhao X, Dalbeth N, Terkeltaub R, Cui L, Liu Z J Inflamm Res. 2024; 17:2657-2668.

PMID: 38707960 PMC: 11069377. DOI: 10.2147/JIR.S458250.


Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study.

Bech-Drewes A, Bonnesen K, Hauge E, Schmidt M Rheumatol Int. 2024; 44(6):1061-1069.

PMID: 38581450 PMC: 11108875. DOI: 10.1007/s00296-024-05584-7.


Gut-immunity-joint axis: a new therapeutic target for gouty arthritis.

Chen P, Luo Z, Lu C, Jian G, Qi X, Xiong H Front Pharmacol. 2024; 15:1353615.

PMID: 38464719 PMC: 10920255. DOI: 10.3389/fphar.2024.1353615.


References
1.
Dehlin M, Jacobsson L, Roddy E . Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16(7):380-390. DOI: 10.1038/s41584-020-0441-1. View

2.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J . 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707. View

3.
Ford J, Solomon D . Challenges in Implementing Treat-to-Target Strategies in Rheumatology. Rheum Dis Clin North Am. 2018; 45(1):101-112. PMC: 8491430. DOI: 10.1016/j.rdc.2018.09.007. View

4.
Qaseem A, Harris R, Forciea M, Denberg T, Barry M, Boyd C . Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016; 166(1):58-68. DOI: 10.7326/M16-0570. View

5.
Dalbeth N, Bardin T, Doherty M, Liote F, Richette P, Saag K . Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017; 13(9):561-568. DOI: 10.1038/nrrheum.2017.126. View